New gel treatment for advanced stomach cancer that has spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new gel called Prospidelong given once into the abdomen during surgery for stomach cancer that has spread to the lining of the belly. The goal is to see if it is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer that has spread to the lining of your belly (peritoneal cavity) but not into your esophagus.
- Your doctor expects you to live at least 6 more months.
- You are able to care for yourself (ECOG score 0 or 1).
- You do not have any serious untreated infections, liver or kidney failure, or other major health problems that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests a combination of low-dose radiation, immunotherapy, chemotherapy, and intraperitoneal perfusion for gastric cancer that has spread to the abdominal lining and is not removable by surgery. It aims to see if this treatment can help control the cancer after first-line chemotherapy has stopped working.
This trial tests a combination of heated chemotherapy placed directly in the abdomen (HIPEC), chemotherapy given through a vein and the abdominal cavity (NIPS), and an immunotherapy drug (tislelizumab) for people with stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink the cancer enough to allow for surgery.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Hear when a new Gastric Cancer With Peritoneal Dissemination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.